Syneos Health AI Leadership Spotlight: Matt Harrington
Matt Harrington
Global Head, Clinical Product, Syneos Health
At Syneos Health, Matt is responsible for defining and delivering the clinical technology product strategy globally, including our AI‑enabled platforms that support study design, startup, execution and oversight.
Matt joined Syneos Health in 2024. He has extensive clinical technology background spanning clinical development, enterprise product leadership and large‑scale platform modernization. His experience centers on translating complex clinical and regulatory requirements into scalable digital products that improve execution, quality and predictability—particularly in highly regulated environments.
Getting to know Matt
Can you briefly describe your primary areas of focus or leadership within technology and AI?
My focus is on product‑led clinical innovation, with AI embedded directly into workflows rather than layered on top. This includes role‑based AI agents, intelligent clinical operations, predictive insights, AI‑assisted content creation and authoring and advanced data surveillance—capabilities designed to reduce manual effort, improve decision quality, and scale expertise across studies.
What unique perspective or expertise do you bring to Syneos Health’s innovation efforts?
I bring a pragmatic, operator‑informed product mindset. That means prioritizing AI where it measurably improves outcomes—cycle time, quality, inspection readiness and user experience—while ensuring solutions are compliant, explainable and adoptable by clinical teams in real‑world delivery settings.
How do you see AI and digital transformation shaping the future of Syneos Health and the broader life sciences industry?
AI is shifting clinical operations from reactive execution to predictive and assistive delivery. At Syneos Health, we’re moving beyond dashboards toward agent‑enabled workflows that proactively surface risks, automate routine work and support better decisions earlier in the trial lifecycle—ultimately improving speed, quality and predictability.
Which recent and upcoming technology initiatives or solutions are you most excited about and why?
I’m particularly excited about our role‑based agents and portals and intelligent TMF Operations. These solutions use AI to automate document classification and filing, surface role‑specific insights and guide users through critical path activities—allowing CRAs, CTMs, PMs and TMF leads to focus on judgment and execution rather than manual coordination.
We’re also advancing AI‑assisted startup and document authoring, where generative AI produces first‑draft, compliant study startup documentation and tasks, accelerating timelines while improving consistency and quality.
What role does ethical AI and governance play in your approach to technology development and deployment?
Ethical AI is foundational. Our approach emphasizes human‑in‑the‑loop design, transparency and clear accountability—particularly for regulated processes such as TMF, safety and data surveillance. AI augments expertise; it doesn’t replace responsibility. Strong governance ensures trust with regulators, sponsors and, most importantly, patients.
What motivates you most about your work in technology and AI?
What motivates me is seeing AI remove friction from clinical delivery, freeing teams to focus on science, problem‑solving and sponsor and patient outcomes. When automation and intelligence meaningfully improve how people work, the impact is tangible and lasting.
Can you share a personal insight or passion that shaped your career journey?
I’ve been shaped by leaders who emphasized that technology only matters if it brings about changes in behaviors, resulting in accelerated results and improved outcomes. That perspective continues to guide my focus on building AI products that are operationally grounded, measurable and scalable—not experimental for experimentation’s sake.
